Blueprint Medicines Announces Publication in The Lancet Oncology
Blueprint Medicines Announces Publication in The Lancet Oncology Showing Durable Clinical Benefits of AYVAKIT™ (avapritinib) in NAVIGATOR Trial Patients with PDGFRA D842V Mutant GIST.
Blueprint Medicines Does Not Receive Approval from FDA for Avapritinib for Treatment of 4L GIST
Blueprint Medicines Does Not Receive Approval from FDA for Avapritinib for Treatment of 4L GIST.